Page last updated: 2024-11-05

2-aminoisobutyric acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

2-aminoisobutyric acid: RN given refers to unlabeled cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

2-aminoisobutyric acid : A rare, non-protein amino acid and end-product of pyrimidine metabolism, excreted in urine and found in some antibiotics of fungal origin. With the exception of a few bacteria, it is non-metabolisable, and therefore used in bioassays. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID6119
CHEMBL ID1230906
CHEBI ID27971
SCHEMBL ID23312
MeSH IDM0262474

Synonyms (92)

Synonym
AC-2694
cb 1637
einecs 200-544-0
nsc 16590
ai3-15082
brn 0506496
BB 0253767
CHEMBL1230906
2-amino-2-methylpropionic acid
CHEBI:27971 ,
2,2-dimethylglycine
inchi=1/c4h9no2/c1-4(2,5)3(6)7/h5h2,1-2h3,(h,6,7
alanine, 2-methyl-
nsc-16590
nsc16590
.alpha.-methylalanine
.alpha.,.alpha.-dimethylglycine
.alpha.-aminoisobutyrate
2-amino-2-methylpropanoic acid
AIB ,
2-methylalanine
propionic acid, 2-amino-2-methyl-
wln: zx1&1&vq
.alpha.-aminoisobutanoic acid
.alpha.-aminoisobutyric acid
2-amino-2-methyl-propanoic acid
62-57-7
2-amino-2-methylpropanoate
C03665
2-aminoisobutyric acid
2-aminoisobutyric acid, 98%
alpha,alpha-dimethylglycine
alpha-methylalanine
DB02952
alpha-aminoisobutanoic acid
alpha-aminoisobutyric acid
A-6036
STK034507
5085F756-CF99-4860-BBBD-469F4BDEF53C
A0323
AKOS000195995
2-amino-isobutyric acid
LMFA01100053
n-me-alanine;n-me-ala-oh; dl-2-amino-iso-butyric acid;h-2-aminoisobutyric acid
A22742
EN300-53414
FT-0671434
a-aminoisobutyric acid
h-aib-oh
unii-1e7zw41iqu
4-04-00-02616 (beilstein handbook reference)
1e7zw41iqu ,
BP-12097
FT-0635088
FT-0611252
AM20100517
857402-27-8
AB00918
S6270
BBL027672
SCHEMBL23312
.alpha.-aminoisobutyric acid [mi]
propanoic acid, 2-amino-2-methyl-
CS-B0930
2-methyl alanine
alpha -aminoisobutyric acid
aminoisobutyric acid
2-amino-2-methyl-propionic acid
DTXSID0058772
2-aminoisobutyrate
J-300332
F8889-8339
mfcd00008049
alpha-aminoisobutyric acid, puriss., >=99.0% (nt)
a-aminoisobutanoic acid
a-aminoisobutanoate
a-methylalanine
a-aminoisobutyrate
alpha-aminoisobutyrate
alpha-aminoisobutanoate
AC8052
HY-Y0124
SY002590
765258-64-8
2-methyl-l-alanine
Q4596860
enzalutamide impurity 15
AS-15790
a,a-dimethylglycine
65503-84-6
nsc-16590;2-methylalanine;h-aib-oh
Z317024776

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" The relative toxic potential of the drug congeners (CsG greater than CsA greater than CsH = CsF = CsA/M17) correlated well with the degree of their accumulation in the hepatocytes during exposure to equimolar drug concentrations."( In vitro toxicity assessment of cyclosporin A and its analogs in a primary rat hepatocyte culture model.
Boelsterli, UA; Bouis, P; Brouillard, JF; Donatsch, P, 1988
)
0.27

Bioavailability

ExcerptReferenceRelevance
" It eliminated hyperglycemia and restored the normal rate of absorption of AIB and 3-o-methyl glucose by the intestine."( Reversal by vanadate of the effect of diabetes on intestinal growth and transport.
Dobish, MP; Hajjar, JJ; Tomicic, TK, 1989
)
0.28
" Similarly, absorption rate index of the amino acid was also significantly lower in the hyperglycemic perfusion phases compared to control euglycemic phase."( Effect of increased glucose load on maternal-fetal transport of alpha-aminoisobutyric acid in the perfused human placenta: in vitro study.
Al-Azemi, MK; Al-Yatama, M; Harouny, AK; Nandakumaran, M; Sugathan, TN, 2002
)
0.31
"Short peptides are important as lead compounds and molecular probes in drug discovery and chemical biology, but their well-known drawbacks, such as high conformational flexibility, protease lability, poor bioavailability and short half-lives in vivo, have prevented their potential from being fully realized."( Stapling of a 3(10)-helix with click chemistry.
Amiry-Moghaddam, M; Ge, NH; Görbitz, CH; Jacobsen, Ø; Klaveness, J; Maekawa, H; Ottersen, OP; Rongved, P, 2011
)
0.37

Dosage Studied

ExcerptRelevanceReference
" The dose-response curves of insulin stimulation assessed by glucose incorporation and alpha-aminoisobutyric acid uptake showed normal responsiveness, and ED50 was significantly shifted to the right in fibroblasts from both patients."( Clarification of signaling pathways mediated by insulin and insulin-like growth factor I receptors in fibroblasts from patients with specific defect in insulin receptor.
Goji, K; Hisatomi, A; Ishibashi, O; Iwasaki, M; Kobayashi, M; Sasaoka, T; Shigeta, Y; Takata, Y, 1988
)
0.27
" When insulin binding was first inhibited by Ab 47-9, dose-response curves for insulin were markedly shifted to the right for glucose uptake, AIB uptake, and thymidine incorporation into DNA."( Actions of insulin and insulinlike growth factors I and II in cultured microvessel endothelial cells from bovine adipose tissue.
Bar, RS; Boes, M; Dake, B; Dolash, S; Siddle, K, 1988
)
0.27
" Likewise, the insulin dose-response relationship confirmed that physiological levels of insulin (less than or equal to 10(2) microU/ml) increased transport by a similar degree."( System A amino acid transport in incubated muscle: effects of insulin and acute uremia.
Karapanos, G; Maroni, BJ; Mitch, WE, 1986
)
0.27
" Dose-response curves of pGRP for amylase release and AIB uptake were found to be biphasic."( Effects of porcine gastrin-releasing peptide on amylase release, 2-deoxyglucose uptake, and alpha-aminoisobutyric acid uptake in mouse pancreatic acini.
Akanuma, Y; Iwamoto, Y; Nakamura, R, 1983
)
0.27
" Dose-response experiments indicate that full stimulation occurs biphasically."( Nerve growth factor-induced stimulation of alpha-aminoisobutyric acid uptake in PC12 cells: relationship to plasma membrane receptor occupancy.
Gunning, PW; Kedes, DH; Shooter, EM, 1982
)
0.26
" The dose-response curve of inactivation of transport or of metabolic function varied with the ROS generator used and conformed to one of two patterns of toxicity: either threshold-dependent or single-hit inactivation."( Localization of damage induced by reactive oxygen species in cultured cells.
Buxser, SE; Decker, DE; Vroegop, SM, 1995
)
0.29
" Dose-response curves were obtained for samples with or without nanoparticles and each energy beam."( Experimental assessment of gold nanoparticle-mediated dose enhancement in radiation therapy beams using electron spin resonance dosimetry.
Baffa, O; Gómez, JA; Guidelli, EJ; Nicolucci, P; Wolfe, T, 2015
)
0.42
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (2)

ClassDescription
2,2-dialkylglycineA non-proteinogenic alpha-amino acid that is glycine substituted by two alkyl groups at position 2.
2,2-dialkylglycine zwitterionThe zwitterionic form of a 2,2-dialkylglycine.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (10)

Processvia Protein(s)Taxonomy
monoatomic ion transportProton-coupled amino acid transporter 1Homo sapiens (human)
amino acid transportProton-coupled amino acid transporter 1Homo sapiens (human)
taurine transmembrane transportProton-coupled amino acid transporter 1Homo sapiens (human)
proline transportProton-coupled amino acid transporter 1Homo sapiens (human)
alanine transportProton-coupled amino acid transporter 1Homo sapiens (human)
amino acid import across plasma membraneProton-coupled amino acid transporter 1Homo sapiens (human)
glycine transportProton-coupled amino acid transporter 1Homo sapiens (human)
proline transmembrane transportProton-coupled amino acid transporter 1Homo sapiens (human)
proton transmembrane transportProton-coupled amino acid transporter 1Homo sapiens (human)
L-alanine transportProton-coupled amino acid transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (9)

Processvia Protein(s)Taxonomy
amino acid:proton symporter activityProton-coupled amino acid transporter 1Homo sapiens (human)
proline:proton symporter activityProton-coupled amino acid transporter 1Homo sapiens (human)
taurine transmembrane transporter activityProton-coupled amino acid transporter 1Homo sapiens (human)
protein bindingProton-coupled amino acid transporter 1Homo sapiens (human)
amino acid transmembrane transporter activityProton-coupled amino acid transporter 1Homo sapiens (human)
alanine transmembrane transporter activityProton-coupled amino acid transporter 1Homo sapiens (human)
L-alanine transmembrane transporter activityProton-coupled amino acid transporter 1Homo sapiens (human)
L-proline transmembrane transporter activityProton-coupled amino acid transporter 1Homo sapiens (human)
glycine transmembrane transporter activityProton-coupled amino acid transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (5)

Processvia Protein(s)Taxonomy
lysosomal membraneProton-coupled amino acid transporter 1Homo sapiens (human)
endoplasmic reticulumProton-coupled amino acid transporter 1Homo sapiens (human)
plasma membraneProton-coupled amino acid transporter 1Homo sapiens (human)
apical plasma membraneProton-coupled amino acid transporter 1Homo sapiens (human)
vacuolar membraneProton-coupled amino acid transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (2)

Assay IDTitleYearJournalArticle
AID630741Inhibition of human PAT1-mediated L-[3H]proline uptake in human Caco2 cells after 10 mins by liquid scintillation counting2011Bioorganic & medicinal chemistry, Nov-01, Volume: 19, Issue:21
Three-dimensional quantitative structure-activity relationship analyses of substrates of the human proton-coupled amino acid transporter 1 (hPAT1).
AID681145TP_TRANSPORTER: uptake in Xenopus laevis oocytes2002Genomics, Jan, Volume: 79, Issue:1
The human T-type amino acid transporter-1: characterization, gene organization, and chromosomal location.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (646)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990283 (43.81)18.7374
1990's195 (30.19)18.2507
2000's81 (12.54)29.6817
2010's79 (12.23)24.3611
2020's8 (1.24)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 33.10

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index33.10 (24.57)
Research Supply Index6.51 (2.92)
Research Growth Index4.36 (4.65)
Search Engine Demand Index50.49 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (33.10)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews11 (1.64%)6.00%
Case Studies4 (0.60%)4.05%
Observational0 (0.00%)0.25%
Other656 (97.76%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]